tiprankstipranks
Trending News
More News >
X4 Pharmaceuticals Inc (XFOR)
NASDAQ:XFOR
Advertisement

X4 Pharmaceuticals (XFOR) AI Stock Analysis

Compare
1,086 Followers

Top Page

XFOR

X4 Pharmaceuticals

(NASDAQ:XFOR)

Rating:44Neutral
Price Target:
X4 Pharmaceuticals faces significant financial challenges, notably in profitability and cash flow, despite growth in revenue. Technical indicators suggest a downward trend, while valuation metrics indicate potential undervaluation. The earnings call and recent corporate events offer some optimism with strategic initiatives and clinical progress, but market and sales challenges remain.
Positive Factors
Financial Performance
The company reported total revenue of $28.8M, compared to the consensus estimate of $11.6M, and a net income of $0.04 per share, compared to the consensus estimated a net loss of $0.12 per share.
Management and Leadership
The appointment of new C-suite management and board of directors, including experienced leaders from CTI BioPharma, is expected to strengthen X4 Pharmaceuticals' position.
Strategic Partnerships
X4 entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of Xolremdi in Europe, Australia, and New Zealand, with potential E.U. approval in 1H26.
Negative Factors
Market Expectations
The analyst is taking a more conservative view of the launch trajectory and commercial opportunity in WHIM syndrome, leading to lowered estimates.
Trial Extension
The most important catalyst for FY25 is the timely completion of patient enrollment into the ongoing P3 4WARD trial, which has been extended.

X4 Pharmaceuticals (XFOR) vs. SPDR S&P 500 ETF (SPY)

X4 Pharmaceuticals Business Overview & Revenue Model

Company DescriptionX4 Pharmaceuticals, Inc. (XFOR) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics aimed at treating rare diseases. The company's primary focus is on diseases characterized by disruptions in immune cell trafficking, including certain types of primary immunodeficiencies. X4's lead product candidate, mavorixafor, is being developed to treat a range of conditions linked to this mechanism, such as WHIM syndrome, a rare immune disorder.
How the Company Makes MoneyX4 Pharmaceuticals generates revenue primarily through the development and commercialization of its pipeline of drug candidates. The company aims to bring its lead product, mavorixafor, to market, which is expected to be a key revenue driver upon approval. Revenue is also derived from strategic collaborations and partnerships with other pharmaceutical companies, which may include milestone payments, research funding, and royalties. Additionally, X4 may earn revenue through licensing agreements for its proprietary technologies and therapies. The company's focus on rare diseases often allows for orphan drug designations, which can provide market exclusivity and potential pricing power in niche markets.

X4 Pharmaceuticals Earnings Call Summary

Earnings Call Date:Jul 31, 2025
(Q1-2025)
|
% Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials and global expansion efforts, supported by a strong financial position and promising market research. However, challenges remain in sales consistency and the brief commercial history in the WHIM market.
Q1-2025 Updates
Positive Updates
Clinical Trial Advancements
X4 advanced the 4WARD Phase III trial for chronic neutropenia (CN), with over 90% of global trial sites activated and a finalized trial design based on regulatory feedback.
US Patent Allowance
Received a notice of allowance from the US patent office for using mavorixafor to treat severe chronic idiopathic and autoimmune neutropenia, with an expiration date in March 2041.
Global Expansion Efforts
Mavorixafor's MAA was accepted by European authorities, with potential EMA approval expected by Q1 2026. New partnerships established for commercialization in Europe, Australia, New Zealand, and the MENA region.
Financial Position
Ended Q1 2025 with nearly $90 million in cash and equivalents, with sufficient funds to support operations into the first half of 2026.
Positive Market Research for CN
Completed a survey with 95 US physicians, revealing higher case loads and a clear unmet need in the CN market.
Negative Updates
Sales Fluctuations
Quarterly sales of XOLREMDI were slightly lower than the previous quarter due to inventory resupply timing and market lumpiness.
Challenges in WHIM Syndrome Market
Despite progress, the commercial history in the WHIM market is still brief, leading to challenges in establishing stable sales patterns.
Company Guidance
During the X4 Pharmaceuticals Q1 2025 financial call, the company provided several key metrics and updates. The 4WARD trial, a pivotal Phase III study for mavorixafor in chronic neutropenia (CN), is actively enrolling participants with over 90% of global trial sites activated. The trial aims to demonstrate statistically significant improvements in absolute neutrophil count (ANC) response and reductions in annualized infection rates, targeting a CN population of about 15,000 in the US with high unmet medical needs. The trial is powered at over 95% for the ANC endpoint and over 90% for infection rate outcomes. X4 anticipates full enrollment by Q3 or Q4 2025, with top-line data expected in H2 2026. Financially, X4 reported ending Q1 with just under $90 million in cash, with cumulative XOLREMDI sales reaching $3.5 million since its May 2024 launch. Additionally, the company highlighted its strategic partnerships for expanding mavorixafor's reach globally, including expected EMA approval by Q1 2026.

X4 Pharmaceuticals Financial Statement Overview

Summary
X4 Pharmaceuticals is showing revenue growth but struggles with profitability and cash flow management. Despite leverage improvements, financial stability concerns persist due to low equity levels and high operational costs.
Income Statement
35
Negative
X4 Pharmaceuticals shows a significant increase in total revenue in TTM (Trailing-Twelve-Months) compared to the previous year, indicating growth in their operations. However, the company has consistently reported negative EBIT and EBITDA figures, reflecting operational inefficiencies. The net profit margin is positive in the TTM period, but historical net losses suggest profitability challenges.
Balance Sheet
40
Negative
The company's debt-to-equity ratio has improved in the TTM period due to reduced total debt, indicating better leverage management. However, the equity ratio remains low, suggesting a higher reliance on liabilities to finance assets. The return on equity is positive in the TTM, but the low stockholders' equity raises concerns about financial stability.
Cash Flow
30
Negative
Operating cash flow has been consistently negative, with a significant cash outflow in the TTM period, indicating cash management issues. Free cash flow remains negative, but the company has managed to generate cash through financing activities. The operating cash flow to net income ratio reflects a disconnect between cash flow generation and reported earnings.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue32.77M2.56M0.000.000.003.00M
Gross Profit27.20M1.76M-2.00M-1.99M-1.89M3.00M
EBITDA-94.22M-27.58M-107.10M-87.57M-84.54M-58.06M
Net Income-101.98M-37.45M-101.17M-93.87M-88.70M-62.13M
Balance Sheet
Total Assets105.17M146.45M147.26M155.59M117.18M122.87M
Cash, Cash Equivalents and Short-Term Investments62.95M102.06M114.22M121.72M81.79M78.71M
Total Debt2.18M78.09M58.28M38.42M39.78M38.45M
Total Liabilities101.20M124.30M96.16M81.53M52.76M50.07M
Stockholders Equity3.97M22.15M51.10M74.05M64.41M72.80M
Cash Flow
Free Cash Flow-112.43M-131.23M-96.57M-77.20M-71.52M-60.18M
Operating Cash Flow-109.30M-130.90M-96.51M-77.10M-70.91M-58.82M
Investing Cash Flow-4.58M66.99M-14.88M-103.00K-615.00K-1.36M
Financing Cash Flow5.77M20.29M88.52M117.23M74.25M12.39M

X4 Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3.64
Price Trends
50DMA
2.26
Positive
100DMA
3.07
Positive
200DMA
8.44
Negative
Market Momentum
MACD
0.44
Positive
RSI
57.99
Neutral
STOCH
29.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XFOR, the sentiment is Positive. The current price of 3.64 is above the 20-day moving average (MA) of 3.10, above the 50-day MA of 2.26, and below the 200-day MA of 8.44, indicating a neutral trend. The MACD of 0.44 indicates Positive momentum. The RSI at 57.99 is Neutral, neither overbought nor oversold. The STOCH value of 29.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XFOR.

X4 Pharmaceuticals Risk Analysis

X4 Pharmaceuticals disclosed 69 risk factors in its most recent earnings report. X4 Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

X4 Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
$72.60M-69.96%-99.64%-59.17%
54
Neutral
$37.21M-277.74%536.44%63.68%
52
Neutral
$58.79M41.08%-5.77%-22.78%
51
Neutral
$7.91B-0.36-41.71%2.23%23.45%-1.86%
45
Neutral
$61.80M108.28%18.51%
44
Neutral
$77.90M0.66-207.22%5721.31%-671.01%
40
Underperform
$41.98M-85.69%10.04%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
XFOR
X4 Pharmaceuticals
3.64
-15.90
-81.37%
KPTI
Karyopharm Therapeutics
6.74
-4.21
-38.45%
NRXP
NRX Pharmaceuticals
2.63
1.00
61.35%
RPTX
Repare Therapeutics
1.69
-1.13
-40.07%
XLO
Xilio Therapeutics
0.72
-0.09
-11.11%
PEPG
PepGen Inc.
1.28
-7.55
-85.50%

X4 Pharmaceuticals Corporate Events

Stock SplitBusiness Operations and StrategyFinancial Disclosures
X4 Pharmaceuticals Reports Q1 2025 Financial Results
Positive
May 1, 2025

On May 1, 2025, X4 Pharmaceuticals reported its financial results for the first quarter of 2025, highlighting significant progress in its clinical trials and commercialization efforts. The company is advancing its Phase 3 4WARD trial for chronic neutropenia and has seen a positive response to its drug XOLREMDI in the U.S. market. Strategic restructuring and international partnerships aim to maximize the potential of mavorixafor, while a recent reverse stock split and improved financial performance position the company for future growth.

Spark’s Take on XFOR Stock

According to Spark, TipRanks’ AI Analyst, XFOR is a Neutral.

X4 Pharmaceuticals’ overall stock score reflects significant challenges in financial performance, as indicated by consistent losses and weak cash flow. Technical indicators suggest downward momentum, and valuation metrics are unfavorable with a negative P/E ratio. While the earnings call presented some positive developments, the net losses and market penetration issues remain major concerns. The strategic restructuring is a step towards cost efficiency but adds uncertainty to the company’s future performance.

To see Spark’s full report on XFOR stock, click here.

Business Operations and Strategy
X4 Pharmaceuticals Announces Strategic Restructuring Plans
Negative
Feb 6, 2025

X4 Pharmaceuticals announced a strategic restructuring on February 6, 2025, involving a workforce reduction of approximately 30%, the closure of its Vienna facility, and a focus on advancing mavorixafor for chronic neutropenia. This restructuring aims to decrease annual spending by $30-35 million and extend the company’s cash runway into the first half of 2026, by streamlining operations to enhance the global market opportunity for mavorixafor.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 03, 2025